Clinical Trial Update: Evaluating the Safety and Immunogenicity of AGS-v PLUS, a Universal Mosquito-Borne Disease and Mosquito Control Vaccine [Phase 1]

View source ↗

Summary

Phase 1 trial update on AGS-v PLUS, a universal vaccine targeting mosquito-borne diseases and mosquito control; study completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mosquito-borne Infectious Diseases

Drugs mentioned

• AGS-v PLUS

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Mosquito-Borne Infectious Diseases | Phase 1 | Status: COMPLETED | Results posted: 2022-04-28